ABVC BIOPHARMA, INC. 8-K

What Happened
ABVC BioPharma, Inc. filed an 8-K reporting the results of its March 26, 2026 annual meeting of shareholders. A quorum was present with 10,612,493 shares represented (41.74% of voting power). Shareholders re‑elected all 11 directors, ratified Simon & Edward, LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved an increase to the company’s Amended and Restated 2016 Equity Incentive Plan to equal 15% of issued and outstanding shares as of the meeting date.

Key Details

• Quorum: 10,612,493 shares represented, equal to 41.74% of voting power.
• Directors: All 11 nominees were re‑elected. Example tallies: Eugene Jiang — 10,523,411 For, 89,082 Withheld; Yu‑Min (Francis) Chung — 10,596,780 For, 15,713 Withheld.
• Auditor ratification: Simon & Edward, LLP reappointed — 10,597,352 For, 12,291 Against, 2,850 Abstain.
• Equity plan approval: Plan increase approved — 9,964,400 For, 643,419 Against, 4,674 Abstain; the plan will be adjusted so the aggregate reserved shares equal 15% of issued and outstanding shares as of the meeting date, with continued annual automatic increases of 5% of shares outstanding starting January 1, 2027 until the cap is reached.

Why It Matters
These outcomes keep the current board and auditor in place, providing continuity in governance and financial oversight. Approval of the equity incentive plan increase expands the pool of shares available for grants to employees, consultants or directors, which can be used for recruitment and retention but may be dilutive to existing shareholders as more shares become issuable. Investors should note the specific vote counts and the quorum level (41.74%) when assessing shareholder support for company governance actions.